OncoMatch/Clinical Trials/NCT06743126
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Is NCT06743126 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for melanoma, cutaneous malignant.
Treatment: IMA203 · nivolumab plus relatlimab · lifileucel · nivolumab · pembrolizumab · ipilimumab · Dacarbazine · temozolomide · paclitaxel · paclitaxel plus carboplatin · Albumin-Bound Paclitaxel — This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF mutation
Patients with BRAF mutation should have been treated with one prior line of BRAF-directed therapy (with or without a MEK inhibitor) prior to initial eligibility assessment, unless deemed not clinically indicated at Investigator's discretion due to concurrent medical condition, prior toxicity, or if declined by the patient
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy — unresectable or metastatic
Disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor, applied either as monotherapy or in combination with other therapies as treatment for unresectable or metastatic cutaneous melanoma
Cannot have received: (IMA203)
Prior treatment with IMA203
Cannot have received: allogenic stem cell transplantation
Prior allogenic stem cell transplantation or solid organ transplantation
Cannot have received: solid organ transplantation
Prior allogenic stem cell transplantation or solid organ transplantation
Lab requirements
Blood counts
Adequate selected organ function per protocol
Kidney function
Adequate selected organ function per protocol
Liver function
Adequate selected organ function per protocol
Adequate selected organ function per protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Phoenix, Arizona
- Honor Health Research Institute · Scottsdale, Arizona
- City of Hope National Medical Center · Duarte, California
- UC San Diego Moores Cancer Center · La Jolla, California
- UCLA Hematology/Oncology · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify